Juno Lighting Inc Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 53 Posts
1 2 3 4
IBB – Challenging 2016, Recovering 2017 And Resurgence In 2018
Article By: Noah Kiedrowski Tuesday, February 6, 2018 3:12 PM EDT
The Biotechnology cohort has finally notched a 52-week high and has made up much of the lost ground during the pummeling from both sides of the political isle during the 2016 presidential race.
In this article: AGN, JNJ, NVO, IBB, REGN, GILD, JUNO, ABBV, KITE
Read
Juno Therapeutics Shares Sky Rocket Following Buyout For $9 Billion
Article By: TickerTV Monday, January 22, 2018 2:36 PM EDT
Shares of Juno Therapeutics sky rocketed on news that they were going to be bought out by Celgene Corp for $9 billion or $87 per share.
In this article: JUNO Also: CELG
Read
Celgene To Buy Juno Therapeutics For Approximately $87 Per Share In Cash
Article By: The Fly Monday, January 22, 2018 9:23 AM EDT
Celgene Corporation and Juno Therapeutics announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno.
In this article: CELG, JUNO
Read
Citi Downgrades Juno To Neutral, Says Potential Takeover Priced In
Article By: The Fly Thursday, January 18, 2018 7:24 AM EDT
Citi analyst Robyn Karnauskas last night downgraded Juno Therapeutics to Neutral from Buy while raising her price target for the shares to $81 from $59.
In this article: JUNO Also: CELG
Read
Juno, CAR-T Peers Rise After Report Of Potential Celgene Deal
Article By: The Fly Wednesday, January 17, 2018 12:59 PM EDT
Shares of Juno Therapeutics are on the rise after the Wall Street Journal reported that the company is in talks to be acquired by Celgene.
In this article: JUNO Also: CELG, GILD, BLUE, CLLS, BLCM
Read
4 Biotech Stocks That More Than Doubled This Year
Article By: Zacks Investment Research Saturday, December 23, 2017 7:50 PM EDT
The biotech industry has been on the comeback trail in 2017 after facing challenges including pricing pressure, rising competition, pipeline setbacks, pricing pressure, slowdown in growth of mature products and generic competition for key drugs.
In this article: JUNO, BLUE, XOMA, PBYI, PIRS, ALNY Also: CELG
Read
3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise
Article By: Arpita Dutt Monday, December 11, 2017 7:45 PM EDT
At the beginning of 2017, expectations were pretty high that the pharma and biotech sector would finally see lots of mergers and acquisitions (M&As). However, that did not happen.
In this article: JUNO, BLUE, INCY Also: SNY, AMGN, JNJ, GILD
Read
E Ford Model T And Personalized Medicine
Article By: Ketan Desai Monday, December 11, 2017 10:35 AM EDT
While technology marches on, the economics of personalized medicines just don’t add up. Will they be like costly trinkets being displayed in a museum that we can watch at a distance but not own?
In this article: JUNO, KITE, EDIT
Read
XBI Breaks Through On A Strong Week For Biotech
Article By: Rod Raynovich Friday, September 29, 2017 7:25 PM EDT
The XBI is up 3.17% this week, 46% YTD, compared to only 1.1% WTD for the IBB. The breakthrough gains for the XBI can be attributed to strong performance of top ten holdings that are primarily mid-caps and M&A prospects.
In this article: BMY, ALNY, BMRN, IBB, AMGN, CELG, CLVS, XBI, JUNO, PBYI, SRPT, BLUE, PTCT, ABBV, FMI
Read
Wells Fargo Sees Little Chance Of Higher Bid For Kite Pharma
Article By: The Fly Monday, August 28, 2017 8:05 PM EDT
Gilead and Kite Pharma have announced that the companies have entered into a definitive agreement pursuant to which the former will acquire the latter for $180 per share in cash.
In this article: GILD, JUNO, KITE, BLUE, CLLS
Read
BIO 2017 International #1: CAR-T Therapies On Solid Tumors
Article By: Rod Raynovich Thursday, June 22, 2017 11:45 PM EDT
CAR-T shows great promise against blood cancers but challenges remain for solid tumors. Bellicum Pharmaceuticals, Bluebird bio, Cellectis SA, Juno Therapeutics, Kite Pharma and Poseida Therapeutics are some of the major companies engaged in CAR-T.
In this article: JUNO, KITE, BLUE, CLLS, BLCM
Read
Late Slide In Tech Mega-Caps Leaves Averages Mixed For Week
Article By: The Fly Saturday, June 10, 2017 10:38 AM EDT
Stocks appeared in line for a slight weekly advance until Friday afternoon, when a sharp decline in a number of mega-cap tech stock pushed the Nasdaq down nearly 2.5% at its low point.
In this article: DFT, DHI, DLR, FOR, JWN, M, THO, VZ, CLDR, AMRI, GIII, NLNK, AAPL, AMZN, FRAN, GOOG, MSFT, YHOO, DVAX, JUNO, BABA, FB, AMBA, GLYC, KITE, BLUE, MIK, ANTM, PLAY, RDUS, LOXO, DLTH, HDS
Read
Biotech Fades After ASCO Abstract Rally
Article By: Rod Raynovich Friday, May 26, 2017 6:29 PM EDT
Biotechs faded today now that the rush of oncology drug news cooled down. Today was dominated by the “red screen” with profit taking mainly in smaller caps and momentum driven oncology stocks.
In this article: MRK, ALNY, ALXN, BMRN, INCY, CELG, CLVS, VRTX, ZIOP, JUNO, PBYI, EPZM, GLYC, KITE, TSRO
Read
ASCO Abstracts Week: Biotech Trends And Hot Stocks
Article By: Rod Raynovich Monday, May 22, 2017 10:58 PM EDT
Today Amgen was down over 2 % on news that its osteoporosis treatment Evenity is unlikely to win FDA approval this year because of a safety risk. Radius Health was up over 6% to $37.30 as their rival drug Tymlos was approved in April.
In this article: MRK, ALNY, IBB, INCY, REGN, AMGN, CLVS, VRTX, FBT, XBI, PUMA, JUNO, EPZM, GLYC, KITE, BLUE, RDUS
Read
Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains On Vertex Deal
Article By: Arpita Dutt Wednesday, March 8, 2017 9:08 AM EDT
A tweet kept the biotech industry on edge with President Donald Trump declaring that he is “working on a new system where there will be competition in the Drug Industry” and “pricing for the American people will come way down”.
In this article: CNCE, IONS, JUNO, CELG Also: VRTX, GILD, BIIB
Read
Juno Therapeutics (JUNO) Shows Positive Early Data In Leukemia Patients
Article By: AO Markets Monday, December 5, 2016 9:21 AM EDT
Juno Therapeutics posted positive preliminary results in patients with ibrutinib-refractory Chronic Lymphocytic Leukemia — CLL. These results were presented at a medical conference at the 58th American Society of Hematology.
In this article: JUNO Also: JNJ, CELG
Read
1 to 16 of 53 Posts
1 2 3 4